Stopping a trial early in oncology: For patients or for industry?

Annals of Oncology

Volumn 20, Issue 2, 2009, Pages 395-396

  Bradbury, P ^a   Meyer, R ^a   Pater, J ^a   Tu, D ^a   Seymour, L ^a   Shepherd, L ^a   Eisenhauer, E ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; LETROZOLE; PLACEBO; TANOMASTAT;

BREAST CANCER; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; EVIDENCE BASED PRACTICE; EXPERIMENTAL THERAPY; HUMAN; LETTER; METHODOLOGY; OVERALL SURVIVAL; PRIORITY JOURNAL;

EID: 60549088719     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn753     Document Type: Letter

References (7)

1. Trotta F, Apolone G, Garattini S, Tafuri G. Stopping a trial early in oncology: For patients or for industry? Ann Oncol 2008; 19: 1347-1353.
2. Moore MJ, Hamm J, Dancey J et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced of metastatic adenocarcinoma of the pancreas: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21: 3296-3302.
3. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-1802.
4. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549-556.
5. Lan G, DeMets D. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659-663.
6. Ingle JN, Tu D, Pater JL et al. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol 2008; 19: 877-882.
7. Pater JL, Goss P, Meyer R. Stopping trials for benefit can (sometimes) benefit patients. J Clin Oncol 2008; 26: 2787-2788.